🇺🇸 FDA
Pipeline program

Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

UKD-IKF-Double-T

Phase 2 small_molecule active

Quick answer

Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion for relapsed/refractory Large B-Cell Lymphoma is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
relapsed/refractory Large B-Cell Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials